U.S. biotechnology company Moderna Inc. said. Wednesday said her COVID-19 vaccine is expected to protect against changes in the novel coronavirus recently discovered in Britain, based on data to date.
“We will be conducting additional tests on the vaccine in the coming weeks to confirm this expectation,” the Massachusetts-based company said in their statement.
They also said that it has tested serum from animals and humans who have been vaccinated with their COVID-19 vaccine against a number of previous variants of the virus that has emerged from the onset of the disease. spread, and found that it “remained just as effective.”
A scientist will be working in the laboratory at Moderna in Cambridge, MA on February 28, 2020. (The Boston Globe / Getty / Kyodo)
Moderna’s two-dose vaccine was put to use in the United States on Monday, following the release of a vaccine made by U.S. pharmaceutical giant Pfizer Inc. and his German partner BioNTech SE.
But the news has been overshadowed by concerns raised about new strains of the virus reported in Britain.
Both Moderna and Pfizer vaccines use a new technology called messenger RNA, or mRNA.
While traditional vaccines secrete a weak or inactive germ in human bodies to stimulate an immune response, mRNA vaccines instruct cells to produce harmless “spike protein” cells similar to one found in humans. novel coronavirus.
The immune system then detects the protein and begins to build up an immune response and makes antibodies to protect against future infection.
Canadian health authorities have also approved the use of the Moderna vaccine. Meanwhile, the U.S. company has an agreement with the Japanese government to give an Asian country enough doses of vaccine for 25 million people.
Related broadcast:
Japan’s daily coronavirus cases exceeded 3,200
Japan to squeeze in from Britain over new coronavirus strain
18% of Japanese universities are still isolated due to pandemic
